Understanding how Borrelia burgdorferi resists treatment
A novel antimicrobial resistance mechanism for Borrelia burgdorferi
This study is looking into how the Lyme disease bacteria can stick around in the body and avoid being treated, which could help find better ways to help people with Lyme disease feel better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10671542 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the bacterium Borrelia burgdorferi, responsible for Lyme disease, can resist treatment and persist in the body. The study focuses on specific genes and proteins that may play a role in the bacterium's ability to evade the immune system and maintain infection. By examining these mechanisms, researchers aim to fill gaps in knowledge about how this pathogen operates and how it can be targeted more effectively. Patients with Lyme disease may benefit from insights gained through this research, potentially leading to improved treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Lyme disease, particularly those experiencing persistent symptoms after treatment.
Not a fit: Patients with Lyme disease who have fully recovered and do not experience any lingering symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Lyme disease and reduce the long-term health impacts on patients.
How similar studies have performed: Previous research has shown promise in understanding bacterial resistance mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Skare, Jon T — Texas A&m University Health Science Ctr
- Study coordinator: Skare, Jon T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.